Significant: Malignancies (e.g. lymphoma, non-melanoma skin cancer), reactivation of viral (e.g. herpes zoster, herpes simplex) or latent infections (e.g. TB), diverticulitis, gastrointestinal perforation, lymphocytopenia, anaemia, neutropenia, increased AST and ALT, lipid elevations (e.g. dose-related increases in total cholesterol, triglycerides, LDL and HDL cholesterol levels), hypersensitivity reactions (e.g. angioedema, urticaria, rash). Rarely, lymphoproliferative disorders.
Blood and lymphatic system disorders: Thrombocytosis.
Gastrointestinal disorders: Gastroenteritis, nausea, abdominal pain.
Investigations: Increased creatine phosphokinase, serum creatinine, and weight.
Nervous system disorders: Headache.
Respiratory, thoracic and mediastinal disorders: URTI.
Skin and subcutaneous tissue disorders: Acne, folliculitis.
Potentially Fatal: Serious bacterial, invasive fungal, viral or opportunistic infections (e.g. pneumonia, UTI, herpes zoster, active pulmonary or extrapulmonary TB, oesophageal candidiasis, pneumocystosis, acute histoplasmosis, cryptococcosis, cytomegalovirus disease, BK virus); increased risk of major adverse CV events (e.g. sudden CV death, MI, stroke); thrombosis (e.g. DVT, pulmonary embolism, arterial thrombosis).